MiNK Therapeutics (INKT) Fundamental Analysis: Revenue, Earnings & Valuation

5.08 / 10

Netural

Fundamental health is fair (5.1/10). Strengths include strong Cash‑MV, high inventory turnover, and solid PB‑ROE. Weaknesses arise from negative Asset‑MV, low Revenue‑MV, and adverse Income‑tax/Profit ratio. Overall, fundamentals are moderate, warranting cautious optimism.

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score1/3

Weight14.02%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value78.03

Score3/3

Weight3.62%

1M Return1.54%

Inventory turnover ratio

Value47.95

Score3/3

Weight18.60%

1M Return6.74%

Gross profit margin (%)

Value36.92

Score1/3

Weight-1.32%

1M Return-0.63%

PB-ROE

Value2.65

Score3/3

Weight29.17%

1M Return9.74%

Income tax / Total profit (%)

Value-5.45

Score1/3

Weight-1.07%

1M Return-0.50%

Fixed assets turnover ratio

Value7895.57

Score3/3

Weight2.40%

1M Return1.06%

Cost of sales ratio (%)

Value70.31

Score3/3

Weight10.76%

1M Return4.32%

Asset-MV

Value-0.49

Score0/3

Weight7.30%

1M Return2.69%

Cash-MV

Value-0.09

Score2/3

Weight16.52%

1M Return5.94%

Is INKT fundamentally strong?

INKT scores 5.08/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -4.25 P/E ratio, -3.73 P/B ratio, and -2.45% earnings growth, these metrics solidify its Netural investment rating.